ABSTRACT
Introduction Although APOE ε4 allele carriage confers a risk of coronary disease, its persistence in human populations might be explained by certain survival advantages (antagonistic pleiotropy).
Hypothesis Combining data from three British cohorts–1946 National Survey of Health and Development (NSHD), Southall and Brent Revised (SABRE) and UK Biobank–we explored whether APOE ε4 carriage associates with beneficial or unfavorable left ventricular (LV) structural and functional parameters by echocardiography and cardiovascular magnetic resonance (CMR) in older age.
Methods Based on the presence of APOE ε4, genotypes were divided into: APOE ε4 (ε2ε4, ε3ε4, ε4ε4) and non-APOE ε4 carriers. Echocardiographic data included: LV ejection fraction, E/e’, systolic and diastolic posterior wall and interventricular septal thickness (LVPWTs/d, IVSs/d), LV mass and the ratio of the LV stroke volume to the LV myocardial volume called myocardial contraction fraction (MCF). CMR data additionally included longitudinal and radial peak diastolic strain rates (PDSR). Generalized linear models explored associations between APOE ε4 genotypes as exposures and echocardiographic/CMR biomarkers as outcomes. As APOE genotype is a genetic instrumental variable (unconfounded), Model 1 was unadjusted; Model 2 was adjusted for factors associated with the outcome (age, sex, and socio-economic position) to yield more precise estimates; and subsequent models were individually adjusted for mediators (body mass index, cardiovascular disease [CVD], high cholesterol and hypertension) to explore mechanistic pathways.
Results 35,568 participants were included. Compared to the non-APOE ε4 group, APOE ε4 carriers had similar cardiac echocardiographic phenotypes in terms of LV EF, E/e’, LVPWTs/d, IVSs/d and LV mass but had a 4% higher MCF (95% confidence interval [CI]: 1–7%, p=0.016) which persisted in Model 2 (95% CI 1–7%, p=0.008) but was attenuated to 3% after adjustment for CVD, diabetes and hypertension (all 95% CI 0–6%; all p<0.070). This was replicated in UK Biobank using CMR data, where APOE ε4 carriers had a 1% higher MCF (95% CI 0-1%, p=0.020) which was attenuated only after adjusting for BMI or diabetes.
Conclusions APOE ε4 carriage associates with improved myocardial performance in older age resulting in greater LV stroke volume generation per 1 mL of myocardium and better longitudinal strain rates compared to non APOE ε4 carriers. This potentially favorable cardiac phenotype adds to the growing number of reported survival advantages attributed to APOE ε4 carriage that might collectively explain its persistence in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the UK Medical Research Council (program codes MC_UU_12019/1; MC_UU_12019/4; MC_UU_12019/5). G.C. is supported by British Heart Foundation (MyoFit46 Special Programme Grant SP/20/2/34841), the Barts Charity HeartOME1000 project grant (MGU0427 / G-001411) and by the NIHR UCL Hospitals Biomedical Research Centre. J.C.M. is directly and indirectly supported by the UCL Hospitals NIHR BRC and Biomedical Research Unit at Barts Hospital respectively. AH receives support from the British Heart Foundation, the Economic and Social Research Council (ESRC), the Horizon 2020 Framework Programme of the European Union, the National Institute on Aging, the National Institute for Health Research University College London Hospitals Biomedical Research Centre, the UK Medical Research Council and works in a unit that receives support from the UK Medical Research Council. DP O'Regan is supported by the Medical Research Council (MC_UP_1605/13); National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; and the British Heart Foundation (RG/19/6/34387, RE/18/4/34215).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Greater Manchester Local Research Ethics Committee and the Scotland Research Ethics Committee Ealing, Hounslow and Spelthorne, Parkside, and University College London Research Ethics Committees Northwest Multi-centre Research Committee (MRCEC)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NSHD data is available from: https://www.nshd.mrc.ac.uk/data, SABRE data is available from https://www.sabrestudy.org/, and UK Biobank data is available from https://www.ukbiobank.ac.uk/.